SCHEMBL6492124

SCHEMBL6492124

CCOc1ccc(COS(C)(=O)=O)c(OC)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
HTT P42858 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
KMT2A Q03164 2/20 0.42
TSHR P16473 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TUBB4A P04350 1/20 0.41
TUBB P07437 1/20 0.41
TUBA3C P0DPH7 1/20 0.41
TUBA1B P68363 1/20 0.41
TUBA4A P68366 1/20 0.41
TUBB4B P68371 1/20 0.41
TUBB3 Q13509 1/20 0.41
TUBB2A Q13885 1/20 0.41
TUBB8 Q3ZCM7 1/20 0.41
TUBA3E Q6PEY2 1/20 0.41
TUBA1A Q71U36 1/20 0.41
TUBA1C Q9BQE3 1/20 0.41
TUBB6 Q9BUF5 1/20 0.41
TUBB2B Q9BVA1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8688214 0.88 APLNR (0.53) KMT2AGAAAPLNRALDH1A1TP53
SCHEMBL17224513 0.82 ALDH1A1 (0.51) KMT2AAPLNRALDH1A1KDM4EMEN1
SCHEMBL6495585 0.82 ALDH1A1 (0.42) LMNAHTTTSHRSMN1; SMN2GAA
SCHEMBL13634446 0.81 APLNR (0.50) LMNAHTTNPSR1KMT2ATSHR
SCHEMBL15414218 0.77 PYCR1 (0.44) LMNAHTTKMT2ATSHRSMN1; SMN2
SCHEMBL15414917 0.77 TRPV4 (0.54) TP53
SCHEMBL6258308 0.75 IDO1 (0.60) GAAALDH1A1TP53CA12CA1
SCHEMBL701717 0.74 APLNR (0.47) HTTKMT2ATSHRTUBB4ATUBB
SCHEMBL6492912 0.74 APLNR (0.47) TSHRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6489248 0.73 HPGD (0.42) LMNAGAAALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD LMNA 3711/4885HTT 2992/4885NPSR1 4348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.